Community Academic Profiles–

Robert Harrington

Back to Profile

Publication Details

  • Effect of platelet inhibition with cangrelor during PCI on ischemic events.

    Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA. N Engl J Med. 2013; 368 (14): 1303-13

    The intensity of antiplatelet therapy during percutaneous coronary intervention (PCI) is an important determinant of PCI-related ischemic complications. Cangrelor is a potent intravenous adenosine diphosphate (ADP)-receptor antagonist that acts rapidly and has quickly reversible effects.

    PubMedID: 23473369

Stanford Medicine Resources:

Footer Links: